Safety outcomes of selective serotonin reuptake inhibitors in adolescent attention-deficit/hyperactivity disorder with comorbid depression: the ASSURE study

BACKGROUND Attention deficit-hyperactivity disorder (ADHD) is related to depressive disorder, and adolescents with both present poor outcomes. However, evidence for the safety of concomitantly using a methylphenidate (MPH) and a selective serotonin reuptake inhibitor (SSRI) among adolescent ADHD patients is limited, a literature gap aimed to address through this investigation. METHODS We conducted a new-user cohort study using a nationwide claims database in South Korea. We identified a study population as adolescents who were diagnosed both ADHD and depressive disorder. MPH-only users were compared with patients who prescribed both a SSRI and a MPH. Fluoxetine and escitalopram users were also compared to find a preferable treatment option. Thirteen outcomes including neuropsychiatric, gastrointestinal, and other events were assessed, taking respiratory tract infection as a negative control outcome. We matched the study groups using a propensity score and used the Cox proportional hazard model to calculate the hazard ratio. Subgroup and sensitivity analyses were conducted in various epidemiologic settings. RESULTS The risks of all the outcomes between the MPH-only and SSRI groups were not significantly different. Regarding SSRI ingredients, the risk of tic disorder was significantly lower in the fluoxetine group than the escitalopram group [HR 0.43 (0.25-0.71)]. However, there was no significant difference in other outcomes between the fluoxetine and escitalopram groups. CONCLUSION The concomitant use of MPHs and SSRIs showed generally safe profiles in adolescent ADHD patients with depression. Most of the differences between fluoxetine and escitalopram, except those concerning tic disorder, were not significant.

[1]  D. Truong,et al.  Medications used to treat tremors , 2022, Journal of the Neurological Sciences.

[2]  J. Morgan,et al.  Drug-induced tremor, clinical features, diagnostic approach and management , 2022, Journal of the Neurological Sciences.

[3]  A. Sjölander,et al.  Selective serotonin reuptake inhibitors and suicidal behaviour: a population-based cohort study , 2021, Neuropsychopharmacology.

[4]  M. Hudgens,et al.  Interpreting the Results of Intention-to-Treat, Per-Protocol, and As-Treated Analyses of Clinical Trials. , 2021, JAMA.

[5]  O. Tucha,et al.  The female side of pharmacotherapy for ADHD—A systematic literature review , 2020, PloS one.

[6]  A. Cipriani,et al.  Antidepressants in Children and Adolescents: Meta-Review of Efficacy, Tolerability and Suicidality in Acute Treatment , 2020, Frontiers in Psychiatry.

[7]  Shuohua Chen,et al.  Association of Age of Onset of Hypertension With Cardiovascular Diseases and Mortality. , 2020, Journal of the American College of Cardiology.

[8]  M. Lapeyre-Mestre,et al.  Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database , 2020, BMC Psychiatry.

[9]  Christoph U. Lehmann,et al.  Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents , 2019, Pediatrics.

[10]  C. Ng,et al.  Co-Morbid Obsessive–Compulsive Disorder and Attention Deficit Hyperactivity Disorder: Neurobiological Commonalities and Treatment Implications , 2019, Front. Psychiatry.

[11]  S. Borgwardt,et al.  Association of antidepressants with brain morphology in early stages of psychosis: an imaging genomics approach , 2019, Scientific Reports.

[12]  G. Martinotti,et al.  The FDA “Black Box” Warning on Antidepressant Suicide Risk in Young Adults: More Harm Than Benefits? , 2019, Front. Psychiatry.

[13]  D. Davydow,et al.  Depression, antidepressants, and the risk of non-valvular atrial fibrillation: A nationwide Danish matched cohort study , 2018, European journal of preventive cardiology.

[14]  P. Balsam,et al.  5-HT2C receptor blockade reverses SSRI-associated basal ganglia dysfunction and potentiates therapeutic efficacy , 2018, Molecular Psychiatry.

[15]  P. Jensen,et al.  Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and Ongoing Management , 2018, Pediatrics.

[16]  A. Wierzbicka,et al.  Effects of Antidepressants on Sleep , 2017, Current Psychiatry Reports.

[17]  M. Bonati,et al.  Comorbidity prevalence and treatment outcome in children and adolescents with ADHD , 2017, European Child & Adolescent Psychiatry.

[18]  R. Rodriguiz,et al.  5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice , 2017, Neuropsychopharmacology.

[19]  R. McIntyre,et al.  The association between methylphenidate treatment and the risk for fracture among young ADHD patients: A nationwide population-based study in Taiwan , 2017, PloS one.

[20]  B. Pennington,et al.  Sex differences in ADHD symptom severity. , 2015, Journal of child psychology and psychiatry, and allied disciplines.

[21]  H. Steiner,et al.  Fluoxetine potentiation of methylphenidate-induced gene regulation in striatal output pathways: Potential role for 5-HT1B receptor , 2015, Neuropharmacology.

[22]  Jun Liu,et al.  A multimodal MRI study of the hippocampus in medication-naive children with ADHD: What connects ADHD and depression? , 2014, Psychiatry Research: Neuroimaging.

[23]  N. Sousa,et al.  Serotonin 2C receptor antagonists induce fast-onset antidepressant effects , 2014, Molecular Psychiatry.

[24]  A. Sjölander,et al.  Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: register based study , 2014, BMJ : British Medical Journal.

[25]  Richard Platt,et al.  A tool for assessing the feasibility of comparative effectiveness research , 2013 .

[26]  E. Penelo,et al.  Age and gender differences of somatic symptoms in children and adolescents* , 2013, Journal of mental health.

[27]  K. Nilsson,et al.  Symptoms of ADHD and depression in a large adolescent population: Co-occurring symptoms and associations to experiences of sexual abuse , 2011, Nordic journal of psychiatry.

[28]  K. Chang,et al.  Antidepressants and Psychostimulants in Pediatric Populations , 2011, Paediatric drugs.

[29]  A. Meyer-Lindenberg,et al.  Dopamine and psychosis: Theory, pathomechanisms and intermediate phenotypes , 2010, Neuroscience & Biobehavioral Reviews.

[30]  K. Chang,et al.  Psychotropic medication exposure and age at onset of bipolar disorder in offspring of parents with bipolar disorder. , 2010, Journal of child and adolescent psychopharmacology.

[31]  M. Toth,et al.  Paradoxical anxiogenic response of juvenile mice to fluoxetine , 2009, Neuropsychopharmacology.

[32]  A. Yoshino,et al.  Serotonin syndrome induced by augmentation of SSRI with methylphenidate , 2008, Psychiatry and clinical neurosciences.

[33]  E. Storch,et al.  SSRI adverse events: How to monitor and manage , 2008, International review of psychiatry.

[34]  S. Montgomery.  Antidepressants and seizures: emphasis on newer agents and clinical implications , 2005, International journal of clinical practice.

[35]  M. Aşoglu,et al.  The emergence of tics during escitalopram and sertraline treatment. , 2005, International clinical psychopharmacology.

[36]  K. Herman,et al.  Children with ADHD and Depression: A Multisource, Multimethod Assessment of Clinical, Social, and Academic Functioning , 2005, Journal of attention disorders.

[37]  H. Jick,et al.  Antidepressants and the risk of suicidal behaviors. , 2004, JAMA.

[38]  M. Robertson,et al.  Antidepressant Treatment of Chronic Tension‐Type Headache: A Comparison Between Fluoxetine and Desipramine , 1998, Headache.

[39]  T. Bougerol,et al.  Citalopram versus fluoxetine: a double‐blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice , 1996, International clinical psychopharmacology.

[40]  J. Sverd,et al.  Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. , 1995, Archives of general psychiatry.

[41]  Sue J. Wilson,et al.  Antidepressants and Sleep , 2012, Drugs.